IgA Nephropathy Clinical Trial
Official title:
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease
The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy [C3G] and IgA Nephropathy [IgAN]). In Part 1 of the study, HVs will receive either one or two doses of ARO-C3 or placebo. In Part 2 of the study, adult patients with C3G/IgAN will receive 3 open-label doses of ARO-C3. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | June 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria (All Participants): - Willing to provide written informed consent and to comply with study requirements - Female participants must be non-pregnant/non-lactating - Healthy volunteers must be willing to be vaccinated with a meningococcal and pneumococcal vaccine. C3G and IgAN participants must have been vaccinated or willing to undergo vaccination - All participants must be willing to be vaccinated or have a history of vaccination for Haemophilus influenzae - Body Mass Index (BMI) between 18.0 and 35.0 kg/m2 - 12-lead electrocardiogram (ECG) at Screening with no abnormalities that may compromise participant's safety at discretion of investigator - Participants of childbearing potential must use highly effective contraception during the study and for at least 12 weeks following the end of the study or last dose of study drug, whichever is later. Males must not donate sperm during the study and for at least 12 weeks following the end of the study or last dose of study drug, whichever is later. - No abnormal finding of clinical relevance at the Screening evaluation that, in the opinion of the investigator, could adversely impact participant safety or study results Inclusion Criteria (C3G and IgAN Participants): - Diagnosis of C3G or IgAN - Clinical evidence of ongoing disease based on significant proteinuria - Estimated glomerular filtration rate =30 mL/Min/1.73 m2 at Screening and currently not on dialysis - Must be on a maximally recommended or tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) Exclusion Criteria (All Participants): - Seropositive for human immunodeficiency virus (HIV) infection,hepatitis B virus, or hepatitis C virus - History of recurrent or chronic infections - Uncontrolled hypertension - Regular use of alcohol within 30 days prior to Screening - Use of illicit drugs within 1 year prior to Screening or positive urine drug screen at Screening - History of meningococcal infection - History of asplenia or splenectomy - Known contraindication or history of anaphylactic reaction to any vaccine or vaccine component or prophylactic antibiotics planned for use in the study - Any medical or surgical condition that, in the opinion of the investigator, would expose the participant to a significant safety risk or compromise the results of the study Note: Additional Inclusion/Exclusion criteria may apply per protocol |
Country | Name | City | State |
---|---|---|---|
Australia | Research Site 1 | Camperdown | New South Wales |
Australia | Research Site 2 | Clayton | Victoria |
Australia | Research Site 3 | Concord | New South Wales |
Georgia | Research Site 1 | Tbilisi | |
Georgia | Research Site 2 | Tbilisi | |
Georgia | Research Site 3 | Tbilisi | |
Germany | Research Site 2 | Cologne | |
Germany | Research Site 4 | Erlangen | |
Germany | Research Site 3 | Halle | |
Germany | Research Site 1 | Mainz | |
Korea, Republic of | Research Site 3 | Daegu | |
Korea, Republic of | Research Site 1 | Gamcheon | Busan |
Korea, Republic of | Research Site 4 | Goyang-si | Gyeonggi-do |
Korea, Republic of | Research Site 2 | Haeundae | Busan |
Korea, Republic of | Research Site 5 | Seongnam | Gyeonggi-do |
Korea, Republic of | Research Site 6 | Soeul | |
Korea, Republic of | Research Site 7 | Soeul | |
Korea, Republic of | Research Site 8 | Soeul | |
New Zealand | Research Site | Auckland | |
Thailand | Research Site 1 | Bangkok | |
Thailand | Research Site 2 | Bangkok | |
Thailand | Research Site 4 | Bangkok | |
Thailand | Research Site 3 | Chiang Mai | |
United Kingdom | Research Site 5 | Cambridge | |
United Kingdom | Research Site 2 | Coventry | |
United Kingdom | Research Site 1 | Leicester | |
United Kingdom | Research Site 3 | Liverpool | |
United Kingdom | Research Site 6 | Newcastle | |
United Kingdom | Research Site 4 | Oxford |
Lead Sponsor | Collaborator |
---|---|
Arrowhead Pharmaceuticals |
Australia, Georgia, Germany, Korea, Republic of, New Zealand, Thailand, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs) at Day 169 | up to day 169 (End of Study [EOS]) | ||
Secondary | Pharmacokinetics (PK) of ARO-C3: Maximum Observed Plasma Concentration (Cmax) | up to 48 hours post-dose | ||
Secondary | PK of ARO-C3: Area under the Plasma Concentration Versus Time Curve from Zero to 24Hours (AUC0-24) | up to 48 hours post-dose | ||
Secondary | PK of ARO-C3: Area Under the Plasma Versus Time Concentration Curve from Zero to the Last Quantifiable Plasma Concentration (AUClast) | up to 48 hours post-dose | ||
Secondary | PK of ARO-C3: Area Under the Plasma Concentration Versus Time Curve from Zero Extrapolated to Infinity (AUCinf) PK of ARO-C3: | up to 48 hours post-dose | ||
Secondary | PK of ARO-C3: Terminal Elimination Half-Life (t1/2) | up to 48 hours post-dose | ||
Secondary | PK of ARO-C3: Apparent Total Body Clearance of ARO-C3 from Plasma (CL) | up to 48 hours post-dose | ||
Secondary | PK of ARO-C3: Volume of Distribution (Vz/F) | up to 48 hours post-dose | ||
Secondary | Pharmacodynamics (PD): Change From Baseline in Complement 3 (C3) up to Day 169 | Baseline, through Day 169 (EOS) | ||
Secondary | PD: Percent Change From Baseline in C3 up to Day 169 | Baseline, through Day 169 (EOS) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05016323 -
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
|
Phase 2 | |
Withdrawn |
NCT02433236 -
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT02231125 -
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
|
Phase 4 | |
Completed |
NCT01502579 -
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
|
N/A | |
Not yet recruiting |
NCT01203007 -
Diet Intervention in Food Sensitive Patients With IgA Nephropathy
|
N/A | |
Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
Completed |
NCT00657059 -
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
|
Phase 3 | |
Recruiting |
NCT04684745 -
Open-Label Extension Study of BION-1301 in IgA Nephropathy
|
Phase 2 | |
Completed |
NCT03719443 -
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT02052219 -
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
|
Phase 3 | |
Completed |
NCT02112838 -
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
|
Phase 2 | |
Completed |
NCT00767221 -
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
|
Phase 2 | |
Recruiting |
NCT04438603 -
The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Terminated |
NCT04905212 -
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
|
Phase 2 | |
Terminated |
NCT04042623 -
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT03633864 -
Fecal Microbiota Transplantation for Refractory IgA Nephropathy
|
Phase 2 | |
Not yet recruiting |
NCT06454110 -
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
|
Phase 2 | |
Recruiting |
NCT02954419 -
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
|
||
Recruiting |
NCT03001947 -
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
|